Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy

HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Proc Natl Acad Sci U S A
المؤلفون الرئيسيون: Floros, Konstantinos V., Lochmann, Timothy L., Hu, Bin, Monterrubio, Carles, Hughes, Mark T., Wells, Jason D., Morales, Cristina Bernadó, Ghotra, Maninderjit S., Costa, Carlotta, Souers, Andrew J., Boikos, Sosipatros A., Leverson, Joel D., Tan, Ming, Serra, Violeta, Koblinski, Jennifer E., Arribas, Joaquin, Prat, Aleix, Paré, Laia, Miller, Todd W., Dozmorov, Mikhail G., Harada, Hisashi, Windle, Brad E., Scaltriti, Maurizio, Faber, Anthony C.
التنسيق: Artigo
اللغة:Inglês
منشور في: National Academy of Sciences 2018
الموضوعات:
PNAS Plus
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856537/
https://ncbi.nlm.nih.gov/pubmed/29476008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1717820115
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة